The Effects of Complete Liver Failure
Complete liver failure results in the progressive deterioration of the quality of the patient’s life. End-Stage Liver Disease (ESLD) causes altered metabolic functions with chronic bodily exhaustion and is coupled with life-threatening (and possibly evolving) encephalopathy. These chronic and progressive bodily symptoms disturb the normal state of living and functioning and cause the patient to become totally dependent and a ward of the health system. Current medical practices mainly deal with the management of acute symptoms, forcing patients to undergo hospital treatment repeatedly to remove accumulated abdominal fluids and manage varices bleeding. Presently, the health system is in great need of new healing practices, and the application of regenerative medicine using UC-MSCs represents such an approach. Patients face a tragic future until these restorative practices become available to heal organ functions; however, seeking care at the best stem cell clinic in Thailand provides these restorative options to patients who have exhausted all curative practices.
Limitations of Conventional Medical Treatments
The only curative treatment for advanced hepatic conditions and End-Stage Liver Disease has traditionally been liver transplantation. Medical practitioners had to rely on drug therapies and liver support machines to prolong the life of the patient, alongside the inevitable and progressive deterioration of the patient’s life. These practices have many disadvantages and difficulty in universal application, as the severe shortage of donor organs results in many patients dying from a lack of available treatment. Furthermore, the recipient of a transplant has to live with a life-threatening illness: loss of control of bodily functions from the effects of powerful immunosuppressive treatments. In addition to the terrible deterioration of the transplanted organ, the already weakened health of the patient is compounded by prolonged surgical recovery. Such limitations require an immediate reconceptualization to regenerative medicine utilizing UC-MSCs at the best stem cell clinic, allowing us to construct hepatic infrastructure rather than replace the organ.
The Justification for Cellular Alternatives
An improvement to cellular therapies will begin to address the complications associated with End-Stage Liver Disease and stimulate restorative processes. There is a strong preference for the use of UC-MSCs (Umbilical Cord – Mesenchymal Stem Cells) at the best stem cell clinic as they contain unique characteristics among other adult cells. Mesenchymal Stem Cells found in umbilical cords are of unique value as they are fully accessible via non-invasive collection and have no ethical issues surrounding their use. Their immunogenicity is extremely low when compared to other cell sources due to the lack of major histocompatibility complex class II on their surface. This unique quality provides the opportunity to perform transplantation across the allogenic spectrum without the induction of severe immune reactions. By using this targeted therapy in Thailand, researchers are focusing on remediating the compromised hepatic microenvironment, eliminating the substantial risks of large invasive surgeries while providing a sustainable therapy to meet clinical demand.
Complex Healing Pathways
Therapy provided by the best stem cell clinic is most effective when the cellular mechanisms that control tissue regeneration are fully understood. Once injected, UC-MSCs migrate to the site of hepatic injury due to local inflammation and the chemokines that are released. When they arrive in the hepatic tissue, they possess the ability to modulate immunity. The cells can inhibit the proliferation of inflammatory T-cells and subsequently the response in End-Stage Liver Disease with the factors that they secrete, namely prostaglandin E2 and indoleamine 2,3-dioxygenase. Moreover, the administered cells engage intimately with hepatic resident stellate cells. In an uninjured liver, stellate cells are quiescent, but with chronic injury, they are activated to synthesize pathological amounts of extracellular matrix proteins, leading to cirrhosis. Therapeutic cells induce apoptosis within these stellate cells, thus stopping the progression of liver fibrosis.
Molecular Remodeling and Tissue Restoration
More than just stopping fibrotic injury in End-Stage Liver Disease, this regenerative pathway demonstrates remodeling at the level of the microenvironment and the matrix. The biological agents derived from UC-MSCs elaborate a plethora of trophic factors, including hepatocyte growth factor and vascular endothelial growth factor. At the matrix, these factors promote the in situ proliferation of endogenous hepatocytes and stimulate neovascularization of the tissue. This framework protects parenchymal tissue from the transit of tissue necrosis. It is noteworthy that the paracrine signaling of exosomes is among the last factors of great importance in tissue restoration utilized at the best stem cell clinic. These vesicles transport microRNAs to the recipient cells of tissue injury and reprogram the cells to promote survival as opposed to apoptosis, reversing the major features of advanced hepatic injury.
Figure 1: Limitations of Conventional Medical Treatments and transition to regenerative UC-MSCs therapy
Future Regional Advancements
Regenerative medicine for End-Stage Liver Disease in Southeast Asia is rapidly changing. Thailand stands out from many nations because of world-class healthcare systems, medical tourism, and being home to the best stem cell clinic. The combination of these factors and government initiatives to support biomedicine utilizing UC-MSCs are a leap toward higher clinical standards. As a result, the best stem cell clinic in Thailand is becoming internationally recognized, attracting highly respected professionals in the field. Researchers are performing painstaking clinical studies to finely tune specific dosing and delivery methods for UC-MSCs. The close working relationships among top academic institutions and focused private medical research facilities speed the important conversion of research lab results to patient care. As more data is collected showing unified and outstanding safety results, Thailand will become the first and the best country to treat End-Stage Liver Disease.